MicroRNAs in skeletal muscle: Their role and regulation in development, disease and function

Journal of Physiology

Volumn 588, Issue 21, 2010, Pages 4075-4087

  Güller, Isabelle ^a   Russell, Aaron P ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

AGING; CELL DIFFERENTIATION; CELL PROLIFERATION; DIABETES MELLITUS; EXERCISE; HUMAN; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE DEVELOPMENT; MUSCLE DISEASE; MUSCLE FUNCTION; MUSCLE HYPERTROPHY; MUSCLE REGENERATION; NONHUMAN; NUTRITION; OBESITY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SKELETAL MUSCLE;

AGING; ANIMALS; DIABETES MELLITUS; EXERCISE; HUMANS; MICRORNAS; MUSCLE DEVELOPMENT; MUSCLE, SKELETAL; MUSCULOSKELETAL DISEASES;

EID: 78049471297     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2010.194175     Document Type: Review

References (105)

1. Adams GR, Haddad F & Baldwin KM (1999). Time course of changes in markers of myogenesis in overloaded rat skeletal muscles. J Appl Physiol 87, 1705-1712.
2. Allen DL, Bandstra ER, Harrison BC, Thorng S, Stodieck LS, Kostenuik PJ, Morony S, Lacey DL, Hammond TG, Leinwand LL, Argraves WS, Bateman TA & Barth JL (2009). Effects of spaceflight on murine skeletal muscle gene expression. J Appl Physiol 106, 582-595.
3. Aoi W, Naito Y, Mizushima K, Takanami Y, Kawai Y, Ichikawa H & Yoshikawa T (2010). The microRNA miR-696 regulates PGC1α in mouse skeletal muscle in response to physical activity. Am J Physiol Endocrinol Metab 298, E799-E806.
4. Banks GB & Chamberlain JS (2008). The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. Curr Top Dev Biol 84, 431-453.
5. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297.
6. Bell ML, Buvoli M & Leinwand LA (2010). Uncoupling of expression of an intronic microRNA and its myosin host gene by exon skipping. Mol Cell Biol 30, 1937-1945.
7. Berkes CA & Tapscott SJ (2005). MyoD and the transcriptional control of myogenesis. Semin Cell Dev Biol 16, 585-595.
8. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD & Glass DJ (2001). Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704-1708.
9. Buckingham M (2006). Myogenic progenitor cells and skeletal myogenesis in vertebrates. Curr Opin Genet Dev 16, 525-532.
10. Callis TE, Deng Z, Chen JF & Wang DZ (2008). Muscling through the microRNA world. Exp Biol Med (Maywood) 233, 131-138.
11. Cardinali B, Castellani L, Fasanaro P, Basso A, Alema S, Martelli F & Falcone G (2009). Microrna-221 and microrna-222 modulate differentiation and maturation of skeletal muscle cells. PLoS One 4, e7607.
12. Chen JF, Callis TE & Wang DZ (2009). microRNAs and muscle disorders. J Cell Sci 122, 13-20.
13. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL & Wang DZ (2006). The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 38, 228-233.
14. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K & Shiekhattar R (2005). TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436, 740-744.
15. Clop A, Marcq F, Takeda H, Pirottin D, Tordoir X, Bibe B, Bouix J, Caiment F, Elsen JM, Eychenne F, Larzul C, Laville E, Meish F, Milenkovic D, Tobin J, Charlier C & Georges M (2006). A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet 38, 813-818.
16. Coffey VG & Hawley JA (2007). The molecular bases of training adaptation. Sports Med 37, 737-763.
17. Corpeleijn E, Saris WH & Blaak EE (2009). Metabolic flexibility in the development of insulin resistance and type 2 diabetes: effects of lifestyle. Obes Rev 10, 178-193.
18. Coyle EF (2000). Physical activity as a metabolic stressor. Am J Clin Nutr 72, 512S-520S.
19. Crist CG, Montarras D, Pallafacchina G, Rocancourt D, Cumano A, Conway SJ & Buckingham M (2009). Muscle stem cell behavior is modified by microRNA-27 regulation of Pax3 expression. Proc Natl Acad Sci U S A 106, 13383-13387.
20. Croce CM & Calin GA (2005). miRNAs, cancer, and stem cell division. Cell 122, 6-7.
21. Di Giovanni S, Molon A, Broccolini A, Melcon G, Mirabella M, Hoffman EP & Servidei S (2004). Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol 55, 195-206.
22. Dogra C, Changotra H, Wedhas N, Qin X, Wergedal JE & Kumar A (2007). TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J 21, 1857-1869.
23. Doucet M, Russell AP, Leger B, Debigare R, Joanisse DR, Caron MA, Leblanc P & Maltais F (2007). Muscle atrophy and hypertrophy signalling in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176, 261-269.
24. Drummond MJ, Glynn EL, Fry CS, Dhanani S, Volpi E & Rasmussen BB (2009). Essential amino acids increase microRNA-499, -208b, and -23a and downregulate myostatin and myocyte enhancer factor 2C mRNA expression in human skeletal muscle. J Nutr 139, 2279-2284.
25. Drummond MJ, McCarthy JJ, Fry CS, Esser KA & Rasmussen BB (2008). Aging differentially affects human skeletal muscle microRNA expression at rest and after an anabolic stimulus of resistance exercise and essential amino acids. Am J Physiol Endocrinol Metab 295, E1333-E1340.
26. Duprey P & Lesens C (1994). Control of skeletal muscle-specific transcription: involvement of paired homeodomain and MADS domain transcription factors. Int J Dev Biol 38, 591-604.
27. Eisenberg I, Alexander MS & Kunkel LM (2009). miRNAS in normal and diseased skeletal muscle. J Cell Mol Med 13, 2-11.
28. Eisenberg I, Eran A, Nishino I, Moggio M, Lamperti C, Amato AA, Lidov HG, Kang PB, North KN, Mitrani-Rosenbaum S, Flanigan KM, Neely LA, Whitney D, Beggs AH, Kohane IS & Kunkel LM (2007). Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci U S A 104, 17016-17021.
29. Elia L, Contu R, Quintavalle M, Varrone F, Chimenti C, Russo MA, Cimino V, De Marinis L, Frustaci A, Catalucci D & Condorelli G (2009). Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 120, 2377-2385.
30. Essen B, Jansson E, Henriksson J, Taylor AW & Saltin B (1975). Metabolic characteristics of fibre types in human skeletal muscle. Acta Physiol Scand 95, 153-165.
31. Fluck M (2006). Functional, structural and molecular plasticity of mammalian skeletal muscle in response to exercise stimuli. J Exp Biol 209, 2239-2248.
32. Fry AC (2004). The role of resistance exercise intensity on muscle fibre adaptations. Sports Med 34, 663-679.
33. Gallagher IJ, Scheele C, Keller P, Nielsen AR, Remenyi J, Fischer CP, Roder K, Babraj J, Wahlestedt C, Hutvagner G, Pedersen BK & Timmons JA (2010). Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes. Genome Med 2, 9.
34. Gambardella S, Rinaldi F, Lepore SM, Viola A, Loro E, Angelini C, Vergani L, Novelli G & Botta A (2010). Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients. J Transl Med 8, 48.
35. Glass DJ (2005). Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 37, 1974-1984.
36. Granjon A, Gustin MP, Rieusset J, Lefai E, Meugnier E, Guller I, Cerutti C, Paultre C, Disse E, Rabasa-Lhoret R, Laville M, Vidal H & Rome S (2009). The microRNA signature in response to insulin reveals its implication in the transcriptional action of insulin in human skeletal muscle and the role of a sterol regulatory element-binding protein-1c/myocyte enhancer factor 2C pathway. Diabetes 58, 2555-2564.
37. Greco AV, Mingrone G, Giancaterini A, Manco M, Morroni M, Cinti S, Granzotto M, Vettor R, Camastra S & Ferrannini E (2002). Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 51, 144-151.
38. Hamilton AJ & Baulcombe DC (1999). A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 286, 950-952.
39. He A, Zhu L, Gupta N, Chang Y & Fang F (2007). Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 21, 2785-2794.
40. Heneghan HM, Miller N & Kerin MJ (2010). Role of microRNAs in obesity and the metabolic syndrome. Obes Rev 11, 354-361.
41. Huang B, Qin W, Zhao B, Shi Y, Yao C, Li J, Xiao H & Jin Y (2009). MicroRNA expression profiling in diabetic GK rat model. Acta Biochim Biophys Sin (Shanghai) 41, 472-477.
42. Jagoe RT & Goldberg AL (2001). What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 4, 183-190.
43. Joseph AM, Pilegaard H, Litvintsev A, Leick L & Hood DA (2006). Control of gene expression and mitochondrial biogenesis in the muscular adaptation to endurance exercise. Essays Biochem 42, 13-29.
44. Khurana TS, Prendergast RA, Alameddine HS, Tome FM, Fardeau M, Arahata K, Sugita H & Kunkel LM (1995). Absence of extraocular muscle pathology in Duchenne's muscular dystrophy: role for calcium homeostasis in extraocular muscle sparing. J Exp Med 182, 467-475.
45. Kim HK, Lee YS, Sivaprasad U, Malhotra A & Dutta A (2006). Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol 174, 677-687.
46. Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z & Hatzigeorgiou A (2004). A combined computational-experimental approach predicts human microRNA targets. Genes Dev 18, 1165-1178.
47. Lamon S, Wallace MA, Leger B & Russell AP (2009). Regulation of STARS and its downstream targets suggest a novel pathway involved in human skeletal muscle hypertrophy and atrophy. J Physiol 587, 1795-1803.
48. Lanza IR, Short DK, Short KR, Raghavakaimal S, Basu R, Joyner MJ, McConnell JP & Nair KS (2008). Endurance exercise as a countermeasure for aging. Diabetes 57, 2933-2942.
49. Latres E, Amini AR, Amini AA, Griffiths J, Martin FJ, Wei Y, Lin HC, Yancopoulos GD & Glass DJ (2005). Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem 280, 2737-2744.
50. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S & Kim VN (2003). The nuclear RNase III Drosha initiates microRNA processing. Nature 425, 415-419.
51. Leger B, Cartoni R, Praz M, Lamon S, Deriaz O, Crettenand A, Gobelet C, Rohmer P, Konzelmann M, Luthi F & Russell AP (2006a). Akt signalling through GSK-3β, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy. J Physiol 576, 923-933.
52. Leger B, Derave W, De Bock K, Hespel P & Russell AP (2008). Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res 11, 163-175B.
53. Leger B, Vergani L, Soraru G, Hespel P, Derave W, Gobelet C, D'Ascenzio C, Angelini C & Russell AP (2006b). Human skeletal muscle atrophy in amyotrophic lateral sclerosis reveals a reduction in Akt and an increase in atrogin-1. FASEB J 20, 583-585.
54. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP & Burge CB (2003). Prediction of mammalian microRNA targets. Cell 115, 787-798.
55. Liu N & Olson EN (2010). MicroRNA regulatory networks in cardiovascular development. Dev Cell 18, 510-525.
56. Liu N, Williams AH, Kim Y, McAnally J, Bezprozvannaya S, Sutherland LB, Richardson JA, Bassel-Duby R & Olson EN (2007). An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. Proc Natl Acad Sci U S A 104, 20844-20849.
57. Lund E, Guttinger S, Calado A, Dahlberg JE & Kutay U (2004). Nuclear export of microRNA precursors. Science 303, 95-98.
58. Lynch GS (2001). Therapies for improving muscle function in neuromuscular disorders. Exerc Sport Sci Rev 29, 141-148.
59. Lynch GS, Rafael JA, Hinkle RT, Cole NM, Chamberlain JS & Faulkner JA (1997). Contractile properties of diaphragm muscle segments from old mdx and old transgenic mdx mice. Am J Physiol Cell Physiol 272, C2063-C2068.
60. Lynn FC (2009). Meta-regulation: microRNA regulation of glucose and lipid metabolism. Trends Endocrinol Metab 20, 452-459.
61. McCarthy JJ & Esser KA (2007). MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J Appl Physiol 102, 306-313.
62. McCarthy JJ, Esser KA & Andrade FH (2007). MicroRNA-206 is overexpressed in the diaphragm but not the hindlimb muscle of mdx mouse. Am J Physiol Cell Physiol 293, C451-C457.
63. McCarthy JJ, Esser KA, Peterson CA & Dupont-Versteegden EE (2009). Evidence of MyomiR network regulation of β-myosin heavy chain gene expression during skeletal muscle atrophy. Physiol Genomics 39, 219-226.
64. McFarlane C, Plummer E, Thomas M, Hennebry A, Ashby M, Ling N, Smith H, Sharma M & Kambadur R (2006). Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism. J Cell Physiol 209, 501-514.
65. Menconi M, Fareed M, O'Neal P, Poylin V, Wei W & Hasselgren PO (2007). Role of glucocorticoids in the molecular regulation of muscle wasting. Crit Care Med 35, S602-608.
66. Moens P, Baatsen PH & Marechal G (1993). Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch. J Muscle Res Cell Motil 14, 446-451.
67. Morissette M, Cook S, Buranasombati C, Rosenberg M & Rosenzweig A (2009). Myostatin inhibits IGF-I induced myotube hypertrophy through Akt. Am J Physiol Cell Physiol 297, C1124-C1132.
68. Naguibneva I, Ameyar-Zazoua M, Polesskaya A, Ait-Si-Ali S, Groisman R, Souidi M, Cuvellier S & Harel-Bellan A (2006). The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation. Nat Cell Biol 8, 278-284.
69. Nakasa T, Ishikawa M, Shi M, Shibuya H, Adachi N & Ochi M (2009). Acceleration of muscle regeneration by local injection of muscle-specific microRNAs in rat skeletal muscle injury model. J Cell Mol Med; DOI:
70. Newton RU & Galvao DA (2008). Exercise in prevention and management of cancer. Curr Treat Options Oncol 9, 135-146.
71. Pandey AK, Agarwal P, Kaur K & Datta M (2009). MicroRNAs in diabetes: tiny players in big disease. Cell Physiol Biochem 23, 221-232.
72. Panguluri SK, Bhatnagar S, Kumar A, McCarthy JJ, Srivastava AK, Cooper NG & Lundy RF (2010). Genomic profiling of messenger RNAs and microRNAs reveals potential mechanisms of TWEAK-induced skeletal muscle wasting in mice. PLoS One 5, e8760.
73. Paroo Z, Ye X, Chen S & Liu Q (2009). Phosphorylation of the human microRNA-generating complex mediates MAPK/Erk signaling. Cell 139, 112-122.
74. Pauley KM, Cha S & Chan EK (2009). MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 32, 189-194.
75. Rao PK, Kumar RM, Farkhondeh M, Baskerville S & Lodish HF (2006). Myogenic factors that regulate expression of muscle-specific microRNAs. Proc Natl Acad Sci U S A 103, 8721-8726.
76. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR & Ruvkun G (2000). The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403, 901-906.
77. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD & Glass DJ (2001). Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 3, 1009-1013.
78. Rosenberg MI, Georges SA, Asawachaicharn A, Analau E & Tapscott SJ (2006). MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206. J Cell Biol 175, 77-85.
79. Russell AP (2005). PGC-1α and exercise: important partners in combating insulin resistance. Curr Diabetes Rev 1, 175-184.
80. Saal S & Harvey SJ (2009). MicroRNAs and the kidney: coming of age. Curr Opin Nephrol Hypertens 18, 317-323.
81. Safdar A, Abadi A, Akhtar M, Hettinga BP & Tarnopolsky MA (2009). miRNA in the regulation of skeletal muscle adaptation to acute endurance exercise in C57Bl/6J male mice. PLoS ONE 4, e5610.
82. Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, Goldberg AL & Spiegelman BM (2006). PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A 103, 16260-16265.
83. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH & Goldberg AL (2004). Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399-412.
84. Schiaffino S & Reggiani C (1996). Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Physiol Rev 76, 371-423.
85. Schwarz DS, Hutvagner G, Haley B & Zamore PD (2002). Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol Cell 10, 537-548.
86. Shimatsu Y, Yoshimura M, Yuasa K, Urasawa N, Tomohiro M, Nakura M, Tanigawa M, Nakamura A & Takeda S (2005). Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ. Acta Myol 24, 145-154.
87. Small EM, O'Rourke JR, Moresi V, Sutherland LB, McAnally J, Gerard RD, Richardson JA & Olson EN (2010). Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486. Proc Natl Acad Sci U S A 107, 4218-4223.
88. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT & Kelly AM (1991). The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352, 536-539.
89. Stein TP & Wade CE (2005). Metabolic consequences of muscle disuse atrophy. J Nutr 135, 1824S-1828S.
90. Sun Q, Zhang Y, Yang G, Chen X, Cao G, Wang J, Sun Y, Zhang P, Fan M, Shao N & Yang X (2008). Transforming growth factor-β-regulated miR-24 promotes skeletal muscle differentiation. Nucleic Acids Res 36, 2690-2699.
91. Thomas M, Langley B, Berry C, Sharma M, Kirk S, Bass J & Kambadur R (2000). Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem 275, 40235-40243.
92. Tintignac LA, Lagirand J, Batonnet S, Sirri V, Leibovitch MP & Leibovitch SA (2005). Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J Biol Chem 280, 2847-2856.
93. Tisdale MJ (2004). Cancer cachexia. Langenbecks Arch Surg 389, 299-305.
94. Tisdale MJ (2007). Is there a common mechanism linking muscle wasting in various disease types? Curr Opin Support Palliat Care 1, 287-292.
95. Van Rooij E, Liu N & Olson EN (2008). MicroRNAs flex their muscles. Trends Genet 24, 159-166.
96. Van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X, Richardson JA, Kelm RJ Jr & Olson EN (2009). A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 17, 662-673.
97. Van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA & Olson EN (2006). A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 103, 18255-18260.
98. Van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J & Olson EN (2007). Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316, 575-579.
99. Webster C, Silberstein L, Hays AP & Blau HM (1988). Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell 52, 503-513.
100. Wilfred BR, Wang WX & Nelson PT (2007). Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol Genet Metab 91, 209-217.
101. Wisloff U, Najjar SM, Ellingsen O, Haram PM, Swoap S, Al-Share Q, Fernstrom M, Rezaei K, Lee SJ, Koch LG & Britton SL (2005). Cardiovascular risk factors emerge after artificial selection for low aerobic capacity. Science 307, 418-420.
102. Yamamoto M & Kuroiwa A (2003). Hoxa-11 and Hoxa-13 are involved in repression of MyoD during limb muscle development. Dev Growth Differ 45, 485-498.
103. Yang W, Chendrimada TP, Wang Q, Higuchi M, Seeburg PH, Shiekhattar R & Nishikura K (2006). Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol 13, 13-21.
104. Yuasa K, Hagiwara Y, Ando M, Nakamura A, Takeda S & Hijikata T (2008). MicroRNA-206 is highly expressed in newly formed muscle fibers: implications regarding potential for muscle regeneration and maturation in muscular dystrophy. Cell Struct Funct 33, 163-169.
105. Zhao Y & Srivastava D (2007). A developmental view of microRNA function. Trends Biochem Sci 32, 189-197.